ReviewNature reviews. Clinical oncology2018
Molecular therapies and precision medicine for hepatocellular carcinoma.
Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,164 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acquisition of Blood and Tumor Tissue Samples From Patients With Hepatobiliary Tumors
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Investigation of Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Biomarker Discovery Through Multiomics Study in Advanced Hepatocellular Carcinoma Patients Who Received Atezolizumab and Bevacizumab Combination Therapy
Role of Fibroblast Growth Factor 21(FGF21) in Breast Cancer
Who cites it
1,164 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,979 citations in OpenAlex.
- Pathological and Perioperative Outcomes of Conversion Hepatectomy After Contemporary Combination Downstaging for Initially Unresectable Hepatocellular Carcinoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration.Frontiers in immunology · 2026Pooled it
- Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.Digestive diseases and sciences · 2025Pooled it
- Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Correlation Between Treatment-Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma.Cancer medicine · 2025Trial
- Current patterns of next-generation sequencing implementation in hepatocellular carcinoma in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Atractylenolide I stabilizes HMOX1 to induce ferroptosis and enhance lenvatinib efficacy in hepatocellular carcinoma.iScience · 2026Article
- Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis-hepatocellular carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Context-dependent modulation of the TAK1-MAPK axis by ginsenoside-based formulations along the NAFLD-HCC continuum.Journal of ginseng research · 2026Article
- Article
- Article
- NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2026Article
- Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy.Journal of gastroenterology · 2026Review
- Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies.Biomedicines · 2026Review
- Molecular Pathophysiology of Hepatocellular Carcinoma: From Metabolic Inflammation to Therapeutic Targets.Cancers · 2026Review
- FBXW8 is upregulated in hepatocellular carcinoma and promotes HCC cell malignancy.BMC gastroenterology · 2026Article
- Cytotoxic Activity ofInternational journal of molecular sciences · 2026Article
- Identification and prognostic analysis of genes related to CTNNB1 mutations in hepatocellular carcinoma.Biology direct · 2026Article
- A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.Experimental hematology & oncology · 2026Article
1,104 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass an annual incidence of 1 million cases. Genomic studies have established the landscape of molecular alterations in HCC; however, the most common mutations are not actionable, and only ~25% of tumours harbour potentially targetable drivers. Despite the fact that surveillance programmes lead to early diagnosis in 40-50% of patients, at a point when potentially curative treatments are applicable, almost half of all patients with HCC ultimately receive systemic therapies. Sorafenib was the first systemic therapy approved for patients with advanced-stage HCC, after a landmark study revealed an improvement in median overall survival from 8 to 11 months. New drugs - lenvatinib in the frontline and regorafenib, cabozantinib, and ramucirumab in the second line - have also been demonstrated to improve clinical outcomes, although the median overall survival remains ~1 year; thus, therapeutic breakthroughs are still needed. Immune-checkpoint inhibitors are now being incorporated into the HCC treatment armamentarium and combinations of molecularly targeted therapies with immunotherapies are emerging as tools to boost the immune response. Research on biomarkers of a response or primary resistance to immunotherapies is also advancing. Herein, we summarize the molecular targets and therapies for the management of HCC and discuss the advancements expected in the near future, including biomarker-driven treatments and immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.